SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors discuss the potential impact of its AI robotics spinoff and VW partnership on the company's future. Community members are analyzing the stock's technical strength, debating short squeeze possibilities, and watching for a breakout. Broader EV sector trends and Rivian's progress towards profitability are also key talking points.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk ($NVO) is trending as investors debate the company's strategy amidst increased competition and a potential bidding war with Pfizer for Metsera. The community is discussing the implications of a possible White House deal on drug pricing and Medicare coverage, as well as the upcoming earnings report. Some traders express concerns about the stock's recent performance, while others see it as a long-term value play in the obesity and diabetes market.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

HOOD is trending as traders anticipate earnings, with many expecting strong numbers due to increased market activity and new offerings like prediction markets. The community is weighing bullish sentiment against potential profit-taking, especially given broader market uncertainty. Some traders also speculate about potential partnerships and the impact of crypto trends on Robinhood's performance.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade Inc. is trending as the community discusses its recent post-earnings move and long-term potential, with some traders noting an overreaction and potential short squeeze while others express skepticism about its profitability. Community members are actively debating whether it can break through key resistance levels soon. Meanwhile, some traders are also monitoring ENVB for a potential short squeeze similar to Beyond Meat's earlier surge.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma ($FIG) is trending after its integration was showcased at the OpenAI DevDay, sparking community excitement about AI-driven design. Bullish investors believe the stock is undervalued compared to competitors like Adobe, while others are wary of its recent IPO and potential for further declines. Community members are actively discussing entry points and whether the OpenAI partnership can reshape Figma's future.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences ($ENVB) is trending as traders discuss its potential as the next short squeeze target, drawing comparisons to past Reddit favorites like $BYND and $AMC. Community chatter highlights the stock's low float and speculation around potential patent payouts, suggesting a possible catalyst for significant upward movement. Some traders are also pointing to recent videos made by YouTubers as a possible reason for the increased attention.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid community excitement around its AI-driven automation platform and recent ISO certification, which validates its AI governance. Discussions revolve around its partnerships with major tech companies like Microsoft and Nvidia, with some anticipating a potential acquisition. Despite positive developments, concerns persist regarding the CEO's ongoing share sales, creating mixed sentiment.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Blockchain Inc

Riot Blockchain is trending as investors debate whether the recent dip is a buying opportunity, especially relative to competitors, and potential manipulation. Community members are closely watching Bitcoin's price movement and upcoming earnings, hoping for positive AI/HPC updates. Some traders express frustration with the stock's price action despite positive news and guidance.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind ($MNKD) is trending as the community discusses the company's revenue potential and recent earnings, with many expressing bullish sentiment and anticipating future growth. Community members are excited about potential catalysts, including pipeline advancements and label expansion, and some are speculating about potential acquisitions. The stock's movement is also attributed to a potential short squeeze.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine ($APPS) is trending as community members discuss the stock's potential, fueled by raised price targets and optimism around AI integration. Discussions also focus on whether $APPS can sustain gains after recent earnings, with some traders pointing to its history of post-earnings volatility. ENVB is getting some attention as a potential Reddit-driven short squeeze play as well.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -20.37% and +69.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability PR Newswire NEW YORK, Oct. 29, 2025...

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...

IOVA Stock Drops 6% on $350M Common Stock Offering

Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline. 

Shares of Iovance Biotherapeutics Inc. (IOVA) traded 4% higher on Tuesday morning after Health Canada approved the company’s immunotherapy for the treatment of advanced melanoma.On Stocktwits, retail sentiment around IOVA rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘low’ levels. According to Stocktwits data, retail chatter around <a href="https://stocktwits.com/symbol/IOVA">IOVA</a> jumped 782% over the past 24 hours as of Tuesday's early hours and by 87% over the past seven days.<figure class="image"><img style="aspect-ratio:626/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_11_53_05_AM_png_6c5efda32c.webp" alt="IOVA's Sentiment Meter and Message Volume as of 11:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="626" height="61"><figcaption>IOVA's Sentiment Meter and Message Volume as of 11:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock would have risen further had it not been for an overall market downturn and said that ‘patience will pay off.’<stembedurl>https://stocktwits.com/katanare/message/625784957</stembedurl>Iovance’s Amtagvi is a T-cell immunotherapy for the treatment of adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy and who have no satisfactory alternative treatment options. Advanced melanoma, also known as metastatic melanoma, refers to melanoma that has spread from the original site to other parts of the body.The marketing authorization in Canada was <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.iovance.com/news-releases/news-release-details/iovances-amtagvir-lifileucel-receives-health-canada-approval">granted</a> based on the safety and efficacy results from a mid-stage trial. The approval is conditional, pending results of trials to confirm its clinical benefit. However, for Iovance, the approval marks its first outside the U.S. “We expect to authorize our first Canadian treatment center within the next few months, and we continue to advance our ex-U.S. strategy for Amtagvi in additional markets,” said CEO Frederick Vogt.Iovance is also investigating Amtagvi in frontline advanced melanoma in a late-stage trial, as well as in additional solid tumor types. IOVA stock is down by 65% this year and by about 77% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/william-blair-highlights-tesla-robotaxi-upsides-versus-uber-waymo/chsgZU4RdgC">William Blair Highlights Tesla Robotaxi’s Upsides Versus Uber, Waymo: Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Iovance Biotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’

The approval from Health Canada is conditional, pending results of trials to confirm the immunotherapy’s clinical benefit.

Equity

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

$HOOD

$APP

$FIG

$SNAP

Which earnings release are you most excited for after the close?  
 
Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.26	--	--	N/A
Q2 '25	-$0.28	-$0.33	-16.70%	MISSED
Q1 '25	-$0.24	-$0.36	-48.93%	MISSED
Q4 '24	-$0.27	-$0.26	2.88%	BEAT
Q3 '24	-$0.30	-$0.28	6.31%	BEAT

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest IOVA News

IOVAIovance Biotherapeutics Inc